CONCLUSION

To the best of our knowledge, this is the first case study of Apatinib treatment for ATC. The prompt and sustained response suggests the possibility that inhibitors targeting VEGFR-2 may be a novel option to control advanced ATC, warranting clinical verifications with larger sample sizes.

Ethics Approval and Consent


Continue Reading

The study was under permission of the ethics committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. Written informed consent was received from the patient for publication including the accompanying data.

Acknowledgment

The authors thank the patient and her family members for their participation in this study.

Disclosure

The authors report no conflicts of interest in this work.


Lin Cheng,1 Qiong Jiao,2 Yuchen Jin,1 Hao Fu,1 Huizhen Zhang,2 Libo Chen1

1Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China; 2Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Correspondence: Libo Chen

Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, People’s Republic of China
Tel +86-21-24058871
Fax +86-21-64941720
Email [email protected]


References

1. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486–497. doi:10.1016/j.clon.2010.03.013

2. Prasongsook N, Kumar A, Chintakuntlawar AV, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metabol. 2017;102(12):4506–4514. doi:10.1210/jc.2017-01180

3. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21(1):25–30. doi:10.1089/thy.2010.0220

4. Ain KB, Egorin MJ, Desimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel phase 2 trial using ninety-six-hour infusion collaborative anaplastic thyroid cancer health intervention trials. Thyroid. 2000;10:587–594. doi:10.1089/thy.2000.10.587

5. Kawada K, Kitagawa K, Kamei S, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol. 2010;40(6):596–599. doi:10.1093/jjco/hyq025

6. Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:1. doi:10.1186/1471-2407-10-529

7. Lin Y, Wang C, Gao W, Cui R, Liang J. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget. 2017;8(26):42252–42261. doi:10.18632/oncotarget.15036

8. Chen W, Xin Z, Xue Y, et al. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer. Endocr Relat Cancer. 2018;25(6):653–663. doi:10.1530/ERC-18-0007

9. Jin Y, Van Nostrand D, Cheng L, Liu M, Chen L. Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol. 2018;125:111–120. doi:10.1016/j.critrevonc.2018.03.012

10. Jin Z, Cheng X, Feng H, et al. Apatinib inhibits angiogenesis via suppressing Akt/GSK3beta/ANG signaling pathway in anaplastic thyroid cancer. Cell Physiol Biochem. 2017;44(4):1471–1484. doi:10.1159/000485583

11. Feng H, Cheng X, Kuang J, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis. 2018;9(10):1030. doi:10.1038/s41419-018-1054-3

12. Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98(1):31–42. doi:10.1210/jc.2012-2909

13. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma–treatment outcome in 75 patients. Radiother Oncol. 2009;92(1):100–104. doi:10.1016/j.radonc.2009.02.016

14. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer. 2006;107(8):1786–1792. doi:10.1002/(ISSN)1097-0142

15. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–1139. doi:10.1089/thy.2012.0302

16. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 1995;11(8):1569–1579.

17. Hu X, Cao J, Hu W, et al. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14(1):820. doi:10.1186/1471-2407-14-820

18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027. doi:10.1200/JCO.2005.06.081

19. Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380. doi:10.1111/j.1349-7006.2011.01939.x

20. Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51(4):223–229. doi:10.1358/dot.2015.51.4.2320599

21. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–371. doi:10.1038/nrm1911

22. Van der Laan B, Freeman JL, Tsang RW, Sylvia L, The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma: evidence for dedifferentiation in tumor progression. Endocr Pathol. 1993;4:215–221. doi:10.1007/BF02915464

23. van der Tuin K, Ventayol Garcia M, Corver WE, et al. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma. Eur J Endocrinol. 2019;180(4):235–241. doi:10.1530/EJE-18-0653

24. Zhang X, Wang C, Lin Y. Pilot dose comparison of Apatinib in Chinese patients with progressive radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metabol. 2018;103(10):3640–3646. doi:10.1210/jc.2018-00381

25. Liu M, Shen Y, Ruan M, Li M, Chen L. Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. Thyroid. 2014;24(7):1179–1183. doi:10.1089/thy.2013.0703

26. Ebihara S, Ebihara T, Kohzuki M. Effect of aging on cough and swallowing reflexes: implications for preventing aspiration pneumonia. Lung. 2012;190(1):29–33. doi:10.1007/s00408-011-9334-z

27. Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25. doi:10.3389/fonc.2017.00025

28. Iniguez-Ariza NM, Ryder MM, Hilger CR, Bible KC. Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer. Thyroid. 2017;27(7):923–927. doi:10.1089/thy.2016.0627

29. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. doi:10.1200/JCO.2017.73.6785

30. Iyer PC, Dadu R, Gule-Monroe M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6(1):68. doi:10.1186/s40425-018-0378-y

31. Iyer PC, Dadu R, Ferrarotto R, et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid. 2018;28(1):79–87. doi:10.1089/thy.2017.0285

32. Kollipara R, Schneider B, Radovich M, Babu S, Kiel PJ. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist. 2017;22(10):1149–1151. doi:10.1634/theoncologist.2017-0096

33. Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014;99(6):2086–2094. doi:10.1210/jc.2013-3588

Source: OncoTargets and Therapy.
Originally published December 2, 2019.

READ FULL ARTICLE Curated publisher From Dovepress